文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

低剂量抗胸腺细胞球蛋白下HLA 1-3个抗原错配相关外周血干细胞移植与无关脐血移植的比较

HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation.
PubMed 文献 · Am J Hematol · 2022-01-03

该研究纳入7861例血液系统恶性肿瘤患者(0至70岁),比较未使用ATG的无关脐血移植(CBT-no ATG,n=7034)与使用低剂量ATG的HLA 1-3个抗原错配相关供者外周血干细胞移植(PBSCT-ATG,n=827)。CBT-no ATG组总生存显著优于PBSCT-ATG组(HR 0.77,p<0.001),但HLA 1个抗原错配的PBSCT-ATG患者总生存与CBT-no ATG组相当。CBT-no ATG组中性粒细胞和血小板植入显著延迟,但非复发死亡率和重度移植物抗宿主病(GVHD)发生率显著更低,两组复发和慢性GVHD发生率相当。结论认为CBT-no ATG可能是优于低剂量ATG下HLA错配相关供者PBSCT的替代选择,而HLA 2-3个抗原错配移植联合低剂量ATG对移植结局有显著不良影响。

要点

  • CBT-no ATG组总生存显著优于PBSCT-ATG组(HR 0.77,p<0.001)。
  • HLA 1个抗原错配的PBSCT-ATG患者总生存与CBT-no ATG组相当。
  • CBT-no ATG组植入延迟但非复发死亡率和重度GVHD发生率显著更低。

核心结论

  • CBT-no ATG可能是优于低剂量ATG下HLA错配相关供者PBSCT的替代移植选择。
  • HLA 2-3个抗原错配相关移植联合低剂量ATG对移植结局有显著不良影响。

研究设计与样本

  • 研究纳入7861例血液系统恶性肿瘤患者,年龄0至70岁。
  • 患者接受未使用ATG的无关脐血移植(CBT-no ATG,n=7034)或使用低剂量ATG的HLA 1-3个抗原错配相关供者外周血干细胞移植(PBSCT-ATG,n=827)。

主要发现

  • CBT-no ATG组总生存显著优于PBSCT-ATG组(HR 0.77,p<0.001)。
  • HLA 1个抗原错配的PBSCT-ATG患者总生存与CBT-no ATG组相当。
  • CBT-no ATG组中性粒细胞和血小板植入显著延迟。
  • CBT-no ATG组非复发死亡率和重度GVHD发生率显著更低。
  • 两组复发和慢性GVHD发生率相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Little information is available regarding whether unrelated cord blood transplantation (CBT) or an HLA 1-3 antigen-mismatched related donor peripheral blood stem-cell transplantation (PBSCT) using low-dose anti-thymocyte globulin (ATG) is superior as an alternative transplantation for patients who lack an HLA-matched sibling or unrelated donor. Therefore, we evaluated 7861 patients with hematologic malignancies (aged 0 to 70 years) who received either a CBT without ATG (CBT-no ATG, n = 7034) or an HLA 1-3 antigen-mismatched related donor PBSCT using low-dose ATG (PBSCT-ATG, n = 827). CBT-no ATG was associated with significantly better overall survival (OS) than the use of a PBSCT-ATG (hazard ratio [HR], 0.77; p < .001), although PBSCT-ATG patients with an HLA 1 antigen-mismatch showed OS comparable to that in the CBT-no ATG group. Neutrophil and platelet engraftment was significantly delayed, whereas the incidences of nonrelapse mortality, and severe graft-versus-host disease (GVHD) were significantly lower in the CBT-no ATG group. The incidences of relapse and chronic GVHD were comparable between these donors. In conclusion, CBT-no ATG may be a better alternative than HLA-mismatched related donor PBSCT using low-dose ATG. Notably, HLA 2-3 antigen mismatch-related transplantation with low-dose ATG had significant adverse effects on transplantation outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Wada F, Watanabe M, Konuma T, et al. HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. Am J Hematol. 2022. PMID: 34978726. doi:10.1002/ajh.26446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。